Systematic review / meta-analysis / 2017
Isoflavone therapy, particularly in aglycone form, significantly attenuated lumbar spine and femoral neck BMD loss in peri- and postmenopausal women.
A systematic review and meta-analysis of 26 RCTs (n = 2652) examined the effect of isoflavone therapies on bone mineral density (BMD) loss in peri- and postmenopausal women. Isoflavone treatment was associated with a significantly higher weighted mean difference (WMD) of BMD change compared with control at the lumbar spine (0.01, 95% CI: 0.01, 0.02; P < 0.00001) and femoral neck (18 RCTs, n = 1604; WMD 0.01, 95% CI: 0.00, 0.02; P < 0.01). In studies providing isoflavones as aglycones, the effect increased at the spine (5 RCTs, n = 682; WMD 0.04, 95% CI: 0.02, 0.05; P < 0.00001) and femoral neck (4 RCTs, n = 524; WMD 0.03, 95% CI: 0.00, 0.06; P < 0.05). The protective effect disappeared when only formulations containing predominantly isoflavone glycosides were analyzed.
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- 2,652 peri- and postmenopausal women across 26 RCTs
- What was measured
- Bone mineral density (BMD) change at the lumbar spine and femoral neck
THE PAPER
A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women.
Lambert MNT, Hu LM, Jeppesen PB. Am J Clin Nutr, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.